Počet záznamů: 1
Omega-3 fatty acids and adipose tissue biology
- 1.
SYSNO ASEP 0496193 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Omega-3 fatty acids and adipose tissue biology Tvůrce(i) Kuda, Ondřej (FGU-C) RID, ORCID, SAI
Rossmeisl, Martin (FGU-C) RID, ORCID
Kopecký, Jan (FGU-C) RID, ORCIDZdroj.dok. Molecular Aspects of Medicine. - : Elsevier - ISSN 0098-2997
Roč. 64, Dec (2018), s. 147-160Poč.str. 14 s. Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova adipocytes ; immunometabolism ; fish oil ; lipid mediators ; bioavailability ; de novo lipogenesis Vědní obor RIV FB - Endokrinologie, diabetologie, metabolizmus, výživa Obor OECD Endocrinology and metabolism (including diabetes, hormones) CEP GA17-11027S GA ČR - Grantová agentura ČR GA16-05151S GA ČR - Grantová agentura ČR LTAUSA17173 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy Institucionální podpora FGU-C - RVO:67985823 UT WOS 000448206400010 EID SCOPUS 85040518305 DOI 10.1016/j.mam.2018.01.004 Anotace This review provides evidence for the importance of white and brown adipose tissue (i.e. WAT and BAT) function for the maintenance of healthy metabolic phenotype and its preservation in response to omega-3 polyunsaturated fatty acids (omega-3 PUFA), namely in the context of diseased states linked to aberrant accumulation of body fat, systemic low-grade inflammation, dyslipidemia and insulin resistance. More specifically, the review deals with (i) the concept of immunometabolism, i.e. how adipose-resident immune cells and adipocytes affect each other and define the immune-metabolic interface, and (ii) the characteristic features of “healthy adipocytes” in WAT, which are relatively small fat cells endowed with a high capacity for mitochondrial oxidative phosphorylation, triacylglycerol/fatty acid (TAG/FA) cycling and de novo lipogenesis (DNL). The intrinsic metabolic features of WAT and their flexible regulations, reflecting the presence of “healthy adipocytes”, provide beneficial local and systemic effects, including (i) protection against in situ endoplasmic reticulum stress and related inflammatory response during activation of adipocyte lipolysis, (ii) prevention of ectopic fat accumulation and dyslipidemia caused by increased hepatic VLDL synthesis, as well as prevention of lipotoxic damage of insulin signaling in extra-adipose tissues, and also (iii) increased synthesis of anti-inflammatory and insulin-sensitizing lipid mediators with pro-resolving properties, including the branched fatty acid esters of hydroxy fatty acids (FAHFAs), also depending on the activity of DNL in WAT. The “healthy adipocytes” phenotype can be induced in WAT of obese mice in response to various stimuli including dietary omega-3 PUFA, especially when combined with moderate calorie restriction, and possibly also with other life style (e.g. physical activity) or pharmacological (e.g. thiazolidinediones) interventions. While omega-3 PUFA could exert beneficial systemic effects by improving immunometabolism of WAT without a concomitant induction of BAT, it is currently not clear whether the metabolic effects of the combined intervention using omega-3 PUFA and calorie restriction or thiazolidinediones depend also on the activation of BAT function and/or the induction of brite/beige adipocytes in WAT. It remains to be established why omega-3 PUFA intervention in type 2 diabetic subjects does not improve insulin sensitivity and glucose homeostasis despite inducing various anti-inflammatory mediators in WAT, including the recently discovered docosahexaenoyl esters of hydroxy linoleic acid, the lipokines from the FAHFA family, as well as several endocannabinoid-related anti-inflammatory lipids. To answer the question whether and to which extent omega-3 PUFA supplementation could promote the formation of “healthy adipocytes” in WAT of human subjects, namely in the obese insulin-resistant patients, represents a challenging task that is of great importance for the treatment of some serious non-communicable diseases. Pracoviště Fyziologický ústav Kontakt Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Rok sběru 2019
Počet záznamů: 1